Efficacy of Remimazolam or Propofol Combined with Sufentanil for Prostate Biopsy in Elderly Men: A Single-Centre, Retrospective Study.

OBJECTIVE

To investigate the efficacy and safety of different anaesthetic drugs in prostate biopsy.

METHODS

The study included patients who underwent prostate biopsy at our hospital from January 2023 to January 2024. All patients received ultrasound-guided transrectal prostate biopsy. The mean arterial pressure (MAP) and heart rate (HR) of the two groups were observed at seven time points: Entering the operating room (T0), starting drug injection (T1), 3 min (T2), 5 min (T3) after drug injection, the end of the operation (T4), entering the PACU (T5) and leaving the PACU (T6). The time from induction to loss of consciousness (A1), the time from induction to bispectral index (BIS) dropping to 60 or lower (A2), the time from drug withdrawal to eye opening (A3), the length of postoperative post-anaesthesia care unit (PACU) stay (A4) and the operation time (A5) were observed. Moreover, the safety of the two groups was compared.

RESULTS

A total of 76 patients were enrolled and divided into two groups: The remimazolam combined with sufentanil (RS) group (n = 37) and the propofol combined with sufentanil (PS) group (n = 39). No significant differences were observed in general data, A1, A2, A3, A4 or A5 between the groups (p > 0.05). Repeated measures analysis of variance (ANOVA) demonstrated significant interaction effects between measurement time and group on MAP and HR (p < 0.05). In addition, significant main effects were observed for time and group (p < 0.05). Simple effect analysis showed no significant differences in MAP and HR at T0 and T1 (p > 0.05). At T2, T3, T4, T5 and T6, the MAP in the RS group was higher than in the PS group (p < 0.05). The HR in the RS group was higher at T2, T3 and T4 (p < 0.05), but exhibited no differences at T5 and T6 (p > 0.05). In terms of safety, the RS group had lower incidences of injection pain and low blood pressure than the PS group (p < 0.05).

CONCLUSIONS

Remimazolam combined with sufentanil provides more stable vital signs and improved safety in elderly men undergoing prostate biopsy, rendering it worthy of promotion.